一个新的MOPSO-GDM框架,以承认阿尔茨海默氏症基于EEG的功能网络
Ruofan Wang1, Haodong Wang1, Lianshuan Shi1
1School of Information Technology Engineering, Tianjin University of Technology and Education, Tianjin, China.
Frontiers in aging neuroscience
|July 17, 2023
概括
这项研究引入了一个新的深度学习框架,使用脑电图 (EEG) 准确检测阿尔茨海默病 (AD). 该方法优化了大脑网络特征,以提高诊断效率.
科学领域:
- 神经科学是一个神经科学.
- 人工智能的人工智能
- 医学诊断 医学诊断 医学诊断
背景情况:
- 阿尔茨海默病 (AD) 诊断是具有挑战性的,因为微妙的,与年龄有关的症状.
- 早期和准确的AD诊断对于有效的治疗和减缓退行至关重要.
研究的目的:
- 开发一种基于EEG的新型分类框架,使用深度学习来识别阿尔茨海默病.
- 通过先进的计算方法提高AD检测的效率和准确性.
主要方法:
- 在五个频段中使用相同步指数 (PSI) 重建多重脑网络.
- 提取了14个拓特征,并使用新的MOPSO-GDM算法对它们进行了优化,考虑了分类错误率和距离测量.
- 采用十倍交叉验证策略进行可靠的评估.
主要成果:
- 实现了5.31%的优异分类错误率,优化的特征向量大小为8.
- 证明了MOPSO-GDM算法在选择最佳大脑网络特征方面的有效性.
结论:
- 拟议的框架适应性地结合了大脑网络特征,以分析网络同步和功能互动.
- 这种方法提高了像阿尔茨海默病这样的神经系统疾病的识别效率.
- 这项研究旨在通过大脑网络分析,深入了解神经疾病中的大脑功能.
更多相关视频
09:38Generalized Psychophysiological Interaction PPI Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease
Published on: November 14, 2017
15.0K
08:43Application of Granger Causality Analysis of the Directed Functional Connection in Alzheimer's Disease and Mild Cognitive Impairment
Published on: August 7, 2017
7.9K
相关概念视频
01:26Alzheimer's Disease: Overview
525
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
525
01:22Alzheimer's Disease: Treatment
219
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
219